西格列汀聯(lián)合二甲雙胍治療2型糖尿病的臨床觀察

謝彩霞

【摘 要】目的：研究西格列汀聯(lián)合二甲雙胍治療2型糖尿病的臨床效果。方法：選擇治療時(shí)間為2017年10月至2018年10月之間的患者人數(shù)為60例，通過進(jìn)行小組劃分方式來區(qū)分治療，分為對(duì)照組與觀察組，其中觀察組采用西格列汀聯(lián)合二甲雙胍進(jìn)行治療，遵醫(yī)囑服用，對(duì)比兩組的并發(fā)癥與治療效果。結(jié)果：研究結(jié)果表明，觀察組整體并發(fā)癥發(fā)生率低于對(duì)照組，整體療效比對(duì)照組好（P<0.05）。結(jié)論：在臨床上，治療2型糖尿病患者可以選擇采用西格列汀配合二甲雙胍藥物，效果顯著，可以在臨床上廣泛推廣應(yīng)用。

【關(guān)鍵詞】西格列汀；二甲雙胍；2型糖尿病；臨床觀察

Clinical observation of sitagliptin combined with metformin in the treatment of type 2 diabetes

Xie Caixia

Qingtongxia People’s Hospital， Qingtongxia Ningxia 751600， China

【Abstract】Objective： To study the clinical effect of sitagliptin combined with metformin in the treatment of type 2 diabetes. Method： 60 patients with treatment time from October 2017 to October 2018 were selected. The treatment was divided into a control group and an observation group by group division. The observation group was treated with sitagliptin combined with metformin and took it as ordered by the doctor.The complications and treatment effects of the two groups were compared. Results： The results of the study showed that the overall complication rate of the observation group was lower than that of the control group， and the overall curative effect was better than that of the control group. Conclusion： In clinical treatment， sitagliptin combined with metformin can be chosen to treat patients with type 2 diabetes， which has significant effects and can be widely used in clinical practice.

【Key？Words】Sitagliptin； Metformin； Type 2 diabetes； Clinical observation

在糖尿病的患病中，每年患有糖尿病患者中，大約有百分之八十九的患者是屬于2型糖尿病情況[1]。伴隨著生活水平的不斷提升，患有糖尿病情況的患者人數(shù)也隨之開始增多。糖尿病是一種臨床代謝性疾病，通過持續(xù)性高血糖作為臨床特征，其具體發(fā)病尚未研究明確[2]。現(xiàn)有研究表明胰島素的分泌缺陷是由于病理、生理等多方面因素所導(dǎo)致的。發(fā)生胰島素下降情況進(jìn)一步造成代謝紊亂。因此可以表明出現(xiàn)糖尿病癥狀可跟胰島素分泌進(jìn)行聯(lián)系[3]。

1 資料與方法

1.1 一般資料

選擇治療時(shí)間為2017年10月至2018年10月之間的患者人數(shù)為60例，通過進(jìn)行小組劃分方式來區(qū)分治療。觀察組，男性13例，女性17例，年齡59歲～72歲，平均年齡（65.35±4.39）歲；對(duì)照組，男性18例，女性12例，年齡61歲～74歲，平均年齡（65.35±4.39）歲。兩組在一般資料對(duì)比上差異不明顯（P>0.05），可進(jìn)行臨床對(duì)比。……